High and Sustained Release of the Novel Echinocandin Rezafungin From Bone Cement: An In Vitro Comparison With Liposomal Amphotericin B and Micafungin
Loading...
Official URL
Full text at PDC
Publication date
2026
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citation
Prats-Peinado, L., Peral, Y., Díaz-Navarro, M., Márquez-Gómez, M., Vaquero-Martín, J., Muñoz, P., Guembe, M., & Sanz-Ruíz, P. (2026). High and Sustained Release of the Novel Echinocandin Rezafungin From Bone Cement: An In Vitro Comparison With Liposomal Amphotericin B and Micafungin. The Journal of Arthroplasty. Advance online publication. https://doi.org/10.1016/j.arth.2026.05.047
Abstract
Background
Fungal periprosthetic joint infections are difficult-to-treat infections due to the complexity of fungal biofilm and to the limited number of antifungal agents that both elute effectively and remain active when incorporated into polymethylmethacrylate (PMMA) bone cement. Rezafungin (REZA), a next-generation, long-acting echinocandin with antibiofilm activity, may overcome these limitations. This study evaluated the in vitro elution kinetics of REZA from PMMA, assessed whether antibiofilm activity was maintained after elution, and compared its performance with micafungin (MICA) and gold standard liposomal amphotericin B (AmB).
Methods
A commercial gentamicin-loaded bone cement was mixed with REZA or MICA at 0.5 and 1% and with AmB at 0.5%. Standardized samples (n = 3 per group) were incubated in phosphate-buffered saline under agitation. Eluates were collected at 10 time points from one hour to six weeks and quantified by liquid chromatography-mass spectrometry (AmB) or high-performance liquid chromatography (MICA and REZA). Cumulative drug release (area under the curve [AUC]) was calculated for each group. The antifungal activity of first-hour eluates of each drug was tested against 12 strains of Candida spp., using a 24-hour biofilm inhibition assay.
Results
The REZA achieved the highest and most sustained elution, with 24-hour concentrations of 1,789 μg/mL (1%) and 1,738 μg/mL (0.5%), exceeding AmB 0.5% by greater than 150-fold. The AUC0-6 weeks ranked: REZA-1 greater than REZA-0.5, greater than MICA, much greater than AmB-0.5. The REZA remained more than 10,000-fold above its minimum inhibitory concentration (minimum inhibitory concentration [MIC] for Candida albicans 0.008 μg/mL) throughout six weeks, while AmB dropped below its MIC (1 μg/mL) after four hours. All antifungals reduced biofilm metabolic activity by greater than 85%, confirming retained antifungal activity.
Conclusions
The REZA eluted from PMMA at high concentrations, releasing significantly more drug than MICA or AmB. Drug release was consistent with a concentration-dependent elution. All three antifungal agents retained metabolic activity, but REZA surpassed its MIC (C albicans) by more than 10,000-fold, a margin that may translate into enhanced antibiofilm activity.
Description
This research was funded by Fundación Mutua Madrileña, grant number FMM24/01, by Fundación SECOT FS24/01 (Sociedad Española de Cirugía Ortopédica y Traumatología), and by Sociedad Española de la Rodilla (SEROD 2024-DON008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Maribel Clemente from the Laboratory Unit, Laura Díaz from the Flow Cytometry Unit and Dolores Serrano from the Faculty of Pharmacy at Universidad Complutense de Madrid, for their technical support.












